VectorY secures €30m EIB loan for neurodegenerative disease therapies
- The EIB signed a €30 million convertible loan agreement with Amsterdam-based VectorY Therapeutics.
- The financing is supported by the European Commission’s InvestEU programme and forms part of a broader financing syndicate.
- VectorY’s platform delivers genetic instructions into central nervous system cells so they can produce therapeutic antibodies.
- Its pipeline targets ALS, Huntington’s disease, frontotemporal dementia and Alzheimer’s disease; its lead ALS programme is in Phase 1/2 clinical development.
Financing and development
The European Investment Bank (EIB) has signed a €30 million convertible loan agreement with Amsterdam-based VectorY Therapeutics. Supported by the European Commission’s InvestEU programme, the financing will help advance the company’s vectorised antibody platform and expand its pipeline. The loan is part of a broader financing syndicate involving new investors and existing shareholders.
Platform and pipeline
VectorY’s platform combines therapeutic antibodies, designed to target disease-associated proteins, with a delivery vehicle that carries genetic instructions into cells in the central nervous system. Those cells can then produce the antibodies themselves. The approach is designed to enable sustained, localised production after a single administration and address limitations of conventional antibody therapies, which typically require repeated injections.
The platform is being developed for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington’s disease, frontotemporal dementia and Alzheimer’s disease. VectorY’s lead programme, VTx-002, targets TDP-43 in ALS and is in Phase 1/2 clinical development. Other pipeline programmes target mutant HTT in Huntington’s disease, TDP-43 in frontotemporal dementia and phosphorylated tau in Alzheimer’s disease.
Source: EIB